Targeted degraders Avilar focuses on extracellular protein degraders using ATACs to target disease-causing extracellular proteins via ASGPR-mediated endolysosomal degradation, presenting an outsourcing opportunity to partners seeking novel modalities beyond traditional small molecules.

Disease focus Preclinical programs include sFlt1 for preeclampsia and IgM-targeting ATACs for anti-MAG neuropathy, highlighting opportunities to partner on specialized indications with high unmet need and potential for accelerated development paths.

Clinical readouts Recent preclinical data and upcoming posters indicate active advancement toward the clinic, suggesting a window to align BD efforts around potential co-development or licensing discussions once IND-enabling data strengthens the case.

Strategic partnerships Founded and financed by RA Capital with key board leadership, Avilar shows readiness for strategic collaborations and potential co-development deals with biotech or pharma partners seeking access to ATAC technology.

Commercial positioning As a small, privately held biotech with a proprietary platform and published preclinical results, Avilar presents a compelling value proposition for early-stage partnerships, licensing of ATAC constructs, or collaboration on payloads targeting extracellular proteomes.